“…It has recently emerged that this innovative method is capable of inducing a more rapid tumor response and lengthening the time of tumor progression compared to treatment with transarterial chemoembolization, suggesting a potential advantage as a bridging therapy in patients waiting for transplantation. 32,33 Although the bridging treatment changed the tumor biology and reduced the risk of tumor progression in our patients, it did not have any effect on survival or tumor recurrence. In addition, the waiting time on the list did not have any effect on the outcome of the transplants, due to it being quite short, on average of 5 months.…”